Abstract: The present invention concerns an objective (10) for imaging an object field of view of 10° onto an imager (12), the objective (10) comprising in order of the propagating direction: —a first lens unit (U1) comprising several lenses, the first lens unit (U1) having a positive first focal length and a first dimension inferior to 15 millimeters, —a bending mirror (M) adapted to bend at a 90° angle, —a liquid lens (LL), and —a second lens unit (U2) comprising several lenses, the second lens unit (U2) having a positive second focal length and a second dimension, the ratio between the first focal length and the second focal length being comprised between 1.0 and 2.0 and the ratio between the first dimension and the second dimension being superior or equal to 2.
Type:
Grant
Filed:
June 28, 2018
Date of Patent:
May 3, 2022
Assignees:
GENSIGHT BIOLOGICS, Sorbonne Université, Centre National de la Recherche Scientifique, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Inventors:
Joël Chavas, Guillaume Chenegros, Charlie Galle
Abstract: The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
Type:
Grant
Filed:
May 13, 2020
Date of Patent:
May 3, 2022
Assignees:
OP2 DRUGS, CENTRE HOSPITALIER UNIVERSITAIRE DE BOURDEAUX, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE BORDEAUX
Inventors:
Philippe Diolez, Dominique Detaille, Frédéric Marin, Olivier Petitjean
Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.
Type:
Grant
Filed:
April 3, 2018
Date of Patent:
May 3, 2022
Assignees:
TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
Inventors:
Serguei Fetissov, Grégory Lambert, Romain Legrand, Nicolas Lucas
Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
May 3, 2022
Assignees:
INSERM (Institut National de la Santéet de la Recherche Médicale), UniversitéPaul Sabatier Toulouse III, Institut Claudius Regaud
Inventors:
Aurelien Olichon, Laura Keller, Gilles Favre, Nicolas Bery, Patrick Chinestra
Abstract: The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.
Type:
Grant
Filed:
February 20, 2017
Date of Patent:
April 26, 2022
Assignees:
INSERM Institut National de la Sante er de la Recherche Medicale, CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Ludivine Perrocheau, Alain Van Dorsselaer, Jose Alain Sahel, Thierry Leveillard
Abstract: The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hc KO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
April 26, 2022
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université Nice Sophia Antipolis, Centre National de la Recherche Scientifique (CNRS)
Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
Type:
Application
Filed:
December 15, 2021
Publication date:
April 21, 2022
Applicants:
INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: The invention relates to a virus-like particle comprising an autoantigen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an autoimmune disease.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
April 19, 2022
Assignees:
Sorbonne Universite, INSERM (Institut National De La Sante Et De La Recherche Medicale), Assistance Publique—Hopitaux De Paris
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
April 12, 2022
Assignees:
Les Laboratories Servier, Institut National de Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifiaue (CNRS)
Abstract: Sarcoglycanopathies are autosomal recessive diseases caused by mutations in the one of the genes coding for any sarcoglycans (SG). The inventors previously showed that the application of small molecules developed to rescue ?F508-CFTR trafficking, and known as CFTR correctors, improved the maturation of several ?-sarcoglycan mutants that were consequently rescued at the plasma membrane (WO 014086687). Now, the inventors show that some specific CFTR correctors provide additive and even synergic effect when administered in combination.
Type:
Grant
Filed:
January 10, 2019
Date of Patent:
April 12, 2022
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE), UNIVERSITE D'EVRY-VAL-D'ESSONNE, GENETHON, UNIVERSITA 'DEGLI STUDI DI PADOVA
Abstract: The present invention relates to the diagnosis of gastrointestinal stromal tumors (GISTs). The present invention also relates to methods and compositions for the treatment of gastrointestinal stromal tumors (GISTs).
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
April 12, 2022
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Pascal De Santa Barbara, Sandrine Faure-De Santa Barbara
Abstract: The present invention relates to the use of at least one tetrafunctional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.
Type:
Application
Filed:
October 15, 2021
Publication date:
April 7, 2022
Applicants:
Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, Centre National de la Recherche Scientifique
Abstract: Interleukin-34 is a cytokine that is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Recent work has also demonstrated a new and possible therapeutic role for IL-34 as a Foxp3+ Treg-secreted cytokine mediator of transplant tolerance. New mutated IL-34 polypeptides have been generated, which can be used as agonists or antagonists.
Type:
Application
Filed:
January 15, 2020
Publication date:
March 31, 2022
Applicants:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE NANTES
Abstract: A local anesthetic chosen from the group of amino amide or amino ester, and a composition or pharmaceutical composition including the local anesthetic. The local anesthetic is for use in the treatment of neurological symptoms resulting from brain dysfunctions such as motor, cognitive, sensory, visual deficits, and/or apathetic, catatonic, vegetative and/or minimally conscious states.
Type:
Application
Filed:
January 22, 2020
Publication date:
March 31, 2022
Applicants:
ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
Inventors:
Laurent COHEN, Randa EL HACHEM, Piirika CREPIN, Guillaume GUERINEAU DE LAMERIE, Gérard SYLVESTRE
Abstract: The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileum microbiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
March 29, 2022
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Université Paul Sabatier Toulouse III
Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
Type:
Grant
Filed:
October 21, 2021
Date of Patent:
March 29, 2022
Assignees:
INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
Abstract: The present invention relates to the use of a cyclic peptide comprising the tripeptide reproducing a binding site of fertilin beta to the oocyte integrin, for improving cellular energy metabolism. More particularly, the invention concerns the use of a cyclic peptide comprising the tripeptide FEEc for stimulating the energy metabolism of gametes or embryonic cells in the context of medically assisted procreation (MAP) protocols, in particular promoting the in vitro maturation of the oocyte, the fertilization rate and the birth rate.
Type:
Grant
Filed:
September 21, 2016
Date of Patent:
March 22, 2022
Assignees:
ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Jean-Philippe Wolf, Anne Lombes, Morgane Bomsel
Abstract: The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.
Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
March 22, 2022
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Inventors:
Mathieu Mevel, David Deniaud, Eduard Ayuso